Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by GoalVest Advisory LLC

GoalVest Advisory LLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3,233.3% during the second quarter, Holdings Channel.com reports. The firm owned 100 shares of the pharmaceutical company’s stock after acquiring an additional 97 shares during the period. GoalVest Advisory LLC’s holdings in Vertex Pharmaceuticals were worth $45,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd raised its position in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the first quarter worth about $32,000. American National Bank & Trust raised its position in Vertex Pharmaceuticals by 515.4% in the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 67 shares in the last quarter. Finally, Solstein Capital LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth about $40,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $420.17 on Tuesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The stock’s 50-day moving average is $399.56 and its two-hundred day moving average is $433.85. The stock has a market cap of $107.73 billion, a PE ratio of 30.03 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the business posted ($12.83) EPS. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on VRTX. Guggenheim dropped their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price target for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Evercore ISI dropped their price target on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. Finally, Citigroup boosted their price target on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $494.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.